BioGend Therapeutics Co., Ltd. AI Stock Analysis
BioGend Therapeutics Co., Ltd. (6733) AI Stock Analysis
BioGend Therapeutics Co., Ltd.
(TPEx:6733)
The score is held back primarily by the company's lack of profitability: despite rapid revenue growth and high gross margins, BioGend still posts an operating margin near -50%, negative return on equity, and annual cash burn that is gradually depleting its equity base. The debt-free balance sheet is a meaningful offset, providing runway and flexibility as losses narrow toward breakeven. Technicals add further caution, with the price trading below all major moving averages amid a persistent downtrend. Valuation offers no support given negative earnings and no dividend, though the low beta of 0.40 limits volatility risk. Earnings call and corporate event data were unavailable and excluded from the calculation.
BioGend Therapeutics Co., Ltd. (6733) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 2.77B
- Dividend Yield
- ―
- Average Volume (3M)
- 73.70K
- Price to Earnings (P/E)
- -38.9
- Beta (1Y)
- 0.40
- Revenue Growth
- 10.74%
- EPS Growth
- 21.61%
- Country
- TW
- Employees
- 34
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
BioGend Therapeutics Co., Ltd. Business Overview & Revenue Model
Company Description
This company specializes in the development of innovative regenerative bio-orthopedic products. Its current pipeline includes BiG-001 and BiG-006, both of which are osteoinductive bone graft substitutes. Additionally, it is advancing BiG-009, an auto...
BioGend Therapeutics Co., Ltd. Financial Statement Overview
Summary
BioGend shows the profile of a commercial-stage but still unprofitable biotech. Revenue has scaled rapidly to NT$222.3 million (+33% year-over-year) with strong ~72% gross margins, and losses have narrowed consistently (net loss down from NT$184.5 million in 2022 to NT$84.6 million). The balance sheet is a genuine strength: essentially debt-free, with equity funding about 91% of assets. However, the company remains loss-making with an operating margin near -50%, negative return on equity of about -11.4%, two consecutive years of gross margin compression, and persistent cash burn (free cash outflow of NT$65.5 million) that is steadily eroding the equity base.
Income Statement
44NeutralBalance Sheet
71PositiveCash Flow
38Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 236.58M | 222.34M | 167.65M | 109.91M | 31.45M | 9.27M |
| Gross Profit | 130.16M | 160.16M | 130.51M | 89.62M | 22.78M | 3.06M |
| EBITDA | -54.31M | -60.73M | -74.38M | -113.94M | -160.62M | -104.71M |
| Net Income | -70.37M | -84.61M | -116.47M | -156.32M | -184.46M | -138.49M |
Balance Sheet | ||||||
| Total Assets | 1.13B | 815.38M | 912.70M | 1.05B | 821.82M | 1.02B |
| Cash, Cash Equivalents and Short-Term Investments | 849.79M | 517.90M | 619.02M | 724.27M | 493.40M | 689.28M |
| Total Debt | 4.76M | 6.58M | 9.43M | 13.09M | 15.77M | 4.42M |
| Total Liabilities | 45.70M | 57.74M | 66.19M | 93.71M | 90.56M | 80.42M |
| Stockholders Equity | 1.07B | 742.09M | 817.67M | 940.96M | 702.86M | 887.54M |
Cash Flow | ||||||
| Free Cash Flow | -50.16M | -65.52M | -99.56M | -164.76M | -186.96M | -137.47M |
| Operating Cash Flow | -47.23M | -63.66M | -98.91M | -138.72M | -168.78M | -136.80M |
| Investing Cash Flow | -384.28M | 66.43M | -8.20M | -89.64M | 201.70M | -134.27M |
| Financing Cash Flow | 356.28M | -3.70M | -3.64M | 396.42M | -4.81M | 287.85M |
BioGend Therapeutics Co., Ltd. Peers Comparison
Overall Rating
- TW:673346Neutral
TW:646142Neutral
TW:665738Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6733 | 46Neutral | TWD 2.80B | -38.91 | ― | ― | 10.74% | 21.61% |
| TW:6461 | 42Neutral | TWD 2.94B | -5.89 | ― | ― | -57.87% | -21.67% |
| TW:6657 | 38Underperform | TWD 2.69B | -8.85 | ― | ― | -4.36% | 1.97% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6733 | BioGend Therapeutics Co., Ltd. | 20.85 | -18.33 | -46.78% | |
| TW:6461 | Intech Biopharm Ltd | 26.55 | 1.66 | 6.65% | |
| TW:6657 | Energenesis Biomedical Co., Ltd. | 30.00 | -11.10 | -27.01% | |
| TW:6926 | Shine-On Biomedical Co., Ltd. | 60.00 | -11.30 | -15.85% | |
| TW:6955 | Bonraybio Co. Ltd. | 86.00 | -47.88 | -35.76% | |
| TW:7427 | Great Novel Therapeutics Biotech & Medicals Corp. | 59.50 | 21.41 | 56.22% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026